Trump said he will raise tariffs on $250 billion in Chinese goods to 30% and hike duties on another $300 billion in products to 15%.Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
The final week of August could be highly volatile as markets fret over the economy and the latest developments in trade wars.Market Insiderread more
Federal Reserve Vice Chair Richard Clarida said Friday that the global economy has deteriorated in the past month.Marketsread more
The latest escalation in the trade war ups the odds the economy will fall into recession and that the Fed will aggressively cut rates.Market Insiderread more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
"We don't need China and, frankly, would be far better off without them," Trump tweeted.Politicsread more
Recent trade friction between the two Asian powerhouses has morphed into a dispute with political implications that go far beyond the region.Asia Politicsread more
"My only question is, who is our bigger enemy, Jay Powell or Chairman Xi?" Trump wrote amid a series of tweets that rattled markets Friday.Politicsread more
"I would love this to be clarified. We come to a deal on trade, boy, this market is up 10 to 15%, but without it's going to be worrisome," Jeremy Siegel says.Marketsread more
Tesla solar energy systems reportedly ignited at an Amazon warehouse in Redlands, California last June, and the Seattle e-commerce titan confirmed that it has no further plans...Technologyread more
(Recasts first paragraph, adds company comment, analyst comment, share price, PIX available)
May 2 (Reuters) - Gilead Sciences Inc, which hired Roche veteran Daniel O'Day to be its new chief executive, on Thursday said Kite Pharma, the cancer-focused cell therapy company it acquired in 2017, will become a separate business unit.
The U.S. drugmaker also reported higher first-quarter earnings as stronger demand pushed sales of its HIV drugs to $3.6 billion from $3.2 billion.
On an adjusted basis, Gilead said it earned $1.76 per share in the quarter, helped by share buybacks. Wall Street analysts, on average, expected $1.61, according to IBES data from Refinitiv.
The results were helped by strong sales of Biktarvy, a new HIV drug, lower-than-expected research and development expenses and a one-time tax benefit, RBC analyst Brian Abrahams said in a research note.
O'Day, leading his first quarterly conference call since taking the Gilead helm on March 1, said the company has initiated a search for a new CEO at Kite, which Gilead bought for $12 billion.
"Kite itself in cell therapy oncology is in an ultracompetitive area," O'Day said. "We have a leadership position, but I think we need to maintain that."
The new CEO said his first priority is strengthening Gilead's drug development pipeline, both internally as well as through acquisitions or partnerships.
Kite is mainly known for Yescarta, a CAR-T cell therapy currently approved to treat certain types of lymphoma.
Gilead said first-quarter sales of Yescarta totaled $96 million, which was short of the average analyst estimate of $103 million.
Sales of Gilead's hepatitis C drugs continued to fall, dropping to $790 million from $1 billion a year earlier.
Once a major growth driver for Gilead, hepatitis C revenue has declined as many patients have been cured of the liver-damaging virus and rival products, particularly from AbbVie, have seized market share from a diminishing patient pool.
Gilead said it still expects relatively flat full-year 2019 product sales of $21.3 billion to $21.8 billion.
Total revenue for the quarter rose to $5.3 billion from $5.1 billion a year earlier, matching Wall Streets forecast.
Net income rose to $2 billion, or $1.54 per share, from $1.5 billion, or $1.17 per share, a year earlier.
Shares of Gilead were up 30 cents at $65.60 in after hours trading. (Reporting By Deena Beasley Editing by Bill Berkrot)